Select Page

Indometacin farnesil

Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin,[1] designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan[2] and Indonesia, under the trade names Infree and Dialon, respectively.

References

  1. ^ Hirohata S, Yanagida T, Kawai M, Kikuchi H (November 1999). "Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil". Immunopharmacology. 44 (3): 245–254. doi:10.1016/S0162-3109(99)00084-3. PMID 10598881.
  2. ^ "Infree (indometacin farnesil capsules) Full Prescribing Information" (PDF). Eisai Co., Ltd. Archived from the original (PDF) on 2010-12-03. from Eisai Co.